[News] Nivolumab plus ipilimumab in metastatic colorectal cancer

Patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer might benefit from combined nivolumab and ipilimumab immunotherapy, according to results from a recent study.

Source: The Lancet Oncology - January 25, 2018 Category: Cancer & Oncology Authors: Elizabeth Gourd Tags: News Source Type: research